Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The difference between retailers and paid shills - like yourself - goalposts are that retailers goalposts most often are timelines of milestones while yours ARE the milestones.
So while milestones are delayed they are getting REACHED and thus retailers were right, while that leads to you guys being EFFECTIVELY wrong.
No data lock - wrong
No TLD - wrong
No journal - wrong
No MIA approval - wrong
No filing for MAA approval- wrong
The ATL-DC in the two UCLA combo trials is not DCVax-L - wrong
And so you continue - as the good non invested paid shills you are - to move your goalposts while "not giving retailers any governance" about your failures. Just ignore, reset, move goalpost.
Ahh yes ... the UK is such a shitty place to get approved.
Why have we moved our predictions? Why are they delayed? Why have our estimations for $ pr share on the short term decreased so much?
Try financial manipulation due to a lawsuit regarding 7 years of spoofing and what that does to a companys possibility to progress ahead on $0,5 pr share instead of $2.51 at data lock. And continous rise as milestones are reached.
Not rocket science, but we all know rational thought and logic is pearl for s..... in this equation.
You are just a bunch of lapdog Judas coin earning pawns, no decency, no conscience, nothing. Pure greed.
9am UK.
NICE DCVax-l Status page back online.
No change…☝️
NICE appraisal page for NWBO is down. https://x.com/peter_brit/status/1792441297980076337?s=46&t=eKWlfJ_s47ckE6GTsb7D0w
You're right, they should be ready to issue immediately. The UK is 5 hours ahead of New York, if they notified NWBO early in the day it would come well before the open, on the other hand if it were late in the day there it would be in the middle of the market day here. The question might then be, do you announce mid day, or stage it the following morning. I can't remember ever seeing such an announcement mid-day, but anything is possible.
Of course it's also possible the company was notified over the weekend, or even Friday, and all is planned for before the open tomorrow. Time will tell, if I'm not up at the market open I'll know something as soon as I see the stock price. Once we have approval I can't believe we'll ever see prices that are at least a couple times over the current price ever again.
Gary
You're right, it's taken longer than we thought back in 2022 and yes $5 would be a nice intermediate goal, but it's far from NWBO's potential, that remains as high as ever, or with the additional information we know now, probably much higher. I'm really not sure that many of us at $5 today won't be worth more than $22 would have been in early 2023. Honestly I don't know if I have over 4 times the shares I had in 2022, but it's certainly a possibility. Even if not, where NWBO is going it won't be long before we're well ahead of where we'd have been with the shares we're working with today.
In reality if I remember correctly in 2022 I needed low double digits to have $1 million in NWBO, now $5 gives me $2 million so for me I do have nearly 4 times the shares I had back then. I'd have never bought all the shares I have today if the shorts and bashers hadn't taken the shares down and held them there. Some here may have added more than me, some less, but in the end those of us who've been on the long side and adding shares will be further ahead than if we'd just moved up in 2023 as we own so many more shares.
Gary
Thanks for your posts. Cheers
I do not think reaching $10 will be difficult after an uplist which should occur after MHRA approval. Before the lawsuit I suspected NYSE though we may instead go back to NASDAQ since we're suing every NYSE Designated Market Maker (DMM) which will not be resolved before regulatory approval. IEX would be ideal but they're no longer in the listing business.
Need anyone say more?
This is the promise of DCVax!!!
All we need now is the great news!!!
Then
And Joel has been treated with the first of his vaccines in 2022
The best possible treatment, in addition to the NHS standard care he has had, is Dendritic Cell Vaccine which is essentially a personalised cancer killing vaccine made from Joel’s own residual tumour ((((((((tissue.receive the treatment from a leading brain tumour Professor from Kings College Hospital in London. Joel had the vaccine in 2022 - we continue to fundraise for future treatments))))))).
And Now
May 2024 -“Stable appearance”.
Joel’s April brain scan continues to show stable post treatment appearance. It is such a relief and extraordinary news. Joel’s oncologist and radiologist at The Christie Hospital can see no changes in the site of his craniotomy. They are now suggesting a slightly longer period between now and his next scan, (later in the autumn). This gives us all an opportunity to get on with living and trying to pack in as many enjoyable experiences as we can.
The bashers move their goalposts??? Really?? I mean REALLY???!!!! How about the cheerleaders and pumpers moving the goalposts???
In 2018 “we are almost there” and “finish line is near” still hearing the same today.
In 2022 most here thought the stock was going to be (average) of $22 at the start of 2023. Now people are hoping for $5. This was according to Gary’s poll.
Crash underride has said “trillion dollar technology” for years and now he says 100 billion.
People have said shorting was the stock price’s issue. Then naked shorting. Then Adam F. Then spoofing. What’s next?? Aliens from Venus probing LP caused the SP to crash??
If one stock is manipulated then every stock is manipulated. The hedge funds wouldn’t single out one stock. If you really think they are spoofing NWBO and no one else you are the dummy in the room. The stock price is what it is based on what Wall Street thinks it’s worth. This stock is worth $.48
Thanks for the reply, Doc
It is really weird that Merck has not released any PR on the p3 trial and in the meantime clinicaltrials.gov was updated with the study results on p3 trial.
Neither BMS nor Roche did it this way.
https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Data-at-ASCO-GU-2024-Showcase-Transformative-Research-in-the-Treatment-of-Genitourinary-Cancers/default.aspx
https://www.globenewswire.com/news-release/2022/08/02/2489970/0/en/Roche-s-subcutaneous-formulation-of-Tecentriq-demonstrates-positive-Phase-III-results.html
ATLnsider
Re: hyperopia post# 692199
Saturday, May 18, 2024 4:20:28 PM
Post#
692493
of 692641
Thanks hyperopia, you may also want to read 1 of my other previous posts regarding DCVax-L along with poly-ICLC:
hyperopia
Re: ATLnsider post# 692493
Sunday, May 19, 2024 2:00:26 PM
Post#
692615
of 692641
Right ATLnsider, as you indicate, in the UCLA combination studies with DCVax-L, the poly-ICLC is administered separately as an adjuvant. However, in the early studies with DCVax-Direct, it was used in the manufacturing process, which increased the potency. (poly I:C, or its derivative, poly-ICLC is included in the Direct patents, and the more recent hyperactive patents)
NW Bio Receives U.S. Patent On Broad Processes For Producing More Potent Dendritic Cells
Next Generation Technology Already In DCVax®-Direct; Will Be Applicable To All DCVax® Products
Building upon the pure immature dendritic cells, NW Bio's patented methods develop mature and activated dendritic cells that are far more potent than dendritic cells produced in the standard way. For example, NW Bio's dendritic cells produce as much as 10X or more the amount of signaling compounds which are key to mobilizing other active agents of the immune system, such as T cells (which infiltrate and attack tumors) and B cells (which produce antibodies).
NW Bio is already using these next generation methods for producing more potent dendritic cells in its production of DCVax-Direct. The same patented methods for activating dendritic cells were also used in the pre-clinical animal studies with DCVax-Direct. In those studies, injection of these potent dendritic cells into some of the tumors in each of the animals resulted in complete clearance of all tumors (both the tumors injected with DCVax-Direct and the tumors not injected) in 80-100% of the animals in the various studies, indicating a system-wide immune response.
?
Going forward, NW Bio's now patented methods of producing more potent dendritic cells will also enable development of the next generation of NW Bio's other two product lines: DCVax-L and DCVax-Prostate. The current DCVax-L and DCVax-Prostate products have already delivered striking results in clinical trials to date, extending the time to tumor recurrence and the patients' survival time by 1-1/2 to 2 years or more, with a substantial portion of patients going far beyond that. Incorporating NW Bio's patented methods for more potent dendritic cells will enable production of enhanced versions of these DCVax-L and DCVax-Prostate products.
https://www.prnewswire.com/news-releases/nw-bio-receives-us-patent-on-broad-processes-for-producing-more-potent-dendritic-cells-198760831.html
For DCVax-L, Northwest Bio uses the most common method of culturing PBMC’s to generate dendritic cells, which relies on the monocytes adhering to the bottom surface of the polystyrene culture vessel in a medium of granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin 4 (IL-4), which induces differentiation into dendritic cells, and activates them.
I believe this increased-potency knowledge was gained in the DCVax-Direct studies because they were attempting to overcome the tumor’s defenses by delaying the activation and maturation of the dendritic cells, which wasn’t possible using culture flasks that are used to produce DCVax-L, so they attempted culturing the monocytes in suspension, in a bagged system without IL-4, using only GM-CSF, and then various other mediums to optimize and activate the dendritic cells, including poly I:C.
Northwest Bio stated that they intended to use this higher potency method across all product lines for the next generation of DCVax, but the Flaskworks’ eden system uses a polystyrene culture cartridge (similar to the well plates used in manual culturing protocols) which the monocytes adhere to, so I’ve not seen evidence that they’ve actually changed the manufacturing method for the next generation of DCVax-L. I believe the method of combining poly-ICLC with DCVax-L requires separate (nearly simultaneous) injections to produce the more potent effect in vivo.
NWBO
Northwest Biotherapeutics Inc (QB)
0.4655
-0.0145 (-3.02%)
Volume: 1,145,477
Day Range: 0.465 - 0.489
Bid: 0.43
Ask: 0.5285
Last Trade Time: 3:59:15 PM EDT
Total Trades: 461
1D
1M
3M
6M
1Y
5Y
Chart for Northwest Biotherapeutics Inc (QB)
NWBO Detailed Quote
Recent NWBO News
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
More NWBO News
InvestorsHub NewsWire
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONG • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174435365
In this post, we can see that the original objective of the 2010 clinical trial, was to determine the best TLR agonist to add as a component in the DCVax-L formulation. Not as an adjuvant treatment, but as a DCVax formulation component. The poly-ICLC would be co-administered along with DCVax-L, at the same time. The poly-ICLC would send “the danger signal”, and would act as an in vivo maturation agent that would mature and hyperactivate the dendritic cell in situ:
https://classic.clinicaltrials.gov/ct2/show/NCT01204684
The main purpose of this study is to evaluate the most effective immunotherapy vaccine components in patients with malignant glioma.
The (sp) investigators previous phase I study (IRB #03-04-053) already confirmed that this vaccine procedure is safe in patients with malignant brain tumors, and with an indication of extended survival in several patients. However, the previous trial design did not allow us to test which formulation of the vaccine was the most effective. This phase II study will attempt to dissect out which components are most effective together
The first trial was a competition to decide which TLR agonist to add to the DCVax-L formulation, either TLR-3 (poly-ICLC) or TLR-7 (imiquimod / resiquimod), as a component in the DCVax-L formulation, to act as an in vivo maturation agent:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568250/
In contrast, we administered the Toll-like receptor (TLR) agonists, imiquimod or poly ICLC, following intradermal injections of ATL-DC to induce DC maturation in vivo. We previously demonstrated in pre-clinical models that the utilization of TLR agonists could enhance the survival and trafficking of DC in situ and enhance the priming of tumor antigen-specific T lymphocytes 31. The findings from this current study suggest that the induction of patient-specific anti-tumor immunity using ATL-DC vaccination and in situ maturation with TLR agonists may represent a preferred formulation for DC-based therapies
The DCVax-L vaccine is administered intradermally, and the poly-ICLC is administered intramuscularly, as illustrated by Dr. Robert Prins in 2014:
Bullish
BULLISH
This is a PSA to all manipulative and collusive Market Makers, Hedge Funds and Short Sellers:
TIME IS RUNNING OUT. THE CLOCK IS TICKING!!!
beartrap12
Re: None
Saturday, May 18, 2024 10:05:57 AM
Post#
692432
of 692639
What are the possibilities that DCVax-L will be approved for new GBM and recurring GBM at one of the next four meeting of the UK’s CHM (Commission on Human Medicines).
They meet on these dates:
May 30-31
June 27-28
July 25-26
Aug. 29-30.
But which is most likely approval day?
Many have already discounted May 30-31, but I think it’s still possible. First, It fits with our submission deadline date of Dec. 25, 2023. May 25 is exactly 150 days from this deadline, but it’s a Saturday, so if UK’s CHM wants to move quickly on DCVax-L, it makes sense that they would approve it at 149 days, rather wait another month for when the commission meets next. Secondly, we received a “validation confirmation” date on May 7th, which just happens to be 2 days before we hit the 80-day completion of Phase 1 of the regulatory process, if you believe the clock started on Dec. 20 when we submitted our application.
But we have since learned that the clock starts when we receive “validation”. Our application passed validation on Jan. 24th, then our validation was “confirmed" on March 7th. The two different validations reported in the quarterly have created some confusion and speculation. I think there is a possibility that the second validation may represent when our application completed Phase I where we received NO request for info from CHM, which means NO need to stop the 150-day clock. Confirm means to check again. That fits with the idea that the first validation was quicker and less thorough and was followed by a more complete examination of the MAA, which ended in the March 7th confirmation and perhaps the end of Phase I. This hypothesis only works if we assume CHM ignored their very late (IMO) Jan. 24 validation and moved quickly to study our MAA.
The second possible CHM meeting on June 27-28 coincides with the first validation date of Jan. 24. 150 days out from Jan. 24 is actually June 22, another Saturday and 5 days before the start of this meeting. If we follow the 150-day law to the letter and believe there is no clock stop for answering questions, then this is the likeliest time to expect the UK to make a decision on our application.
The third possible CHM meeting date, July 25-26, somewhat aligns with the possibility that the clock started when our validation was “confirmed” on March 7th. 150 days out from that confirmation is actually July 29, a Monday. If CHM members wanted to move along our MAA, they could choose to make their decision the weekend before completion of the 150-day time table and hear it on July 25-26.
If they decide not to make a decision on our MAA a weekend early, they would have to wait almost a month until their next meeting on Aug. 29-30. I don’t see that happening unless they are trying to give our automated system another month to complete validation.
None of these dates address the possibility that NWBO may need to stop the clock to respond to a request for information letter from the UK. If this happens it could add 60 or even 120 days to the approval process. I think a clock stop at this point is unlikely, given the comments by Les and in the quarterly. Both were very bullish comments. NWBO has been very cagey about appearing bullish because so many negative shorts have attacked the company and even reported them to regulators when they’ve committed lesser infractions. If the clock started on Dec. 25 or on Jan. 24, in both cases, we would have completed the 80-day phase I long before the time we received the quarterly on May 10 and heard Les speak on May 9. If we accept the March 7th date for when the 150-day clock began, we would have been about 2 weeks before completion of Ph. 1 I believe the rules state that companies receive a request for info only after Ph 1 is complete. I think it’s unlikely Les would have been so bullish as to state “no news is good news” and the quarterly would have told us they had not changed a thing in our MAA if they knew the potential clock-stopping news was still in the future.
Of course, all of this assumes CHM doesn't set a special meeting for NWBO's application.
Bullish
BULLISH
I've got a nice bottle of Irish Whiskey I'll be sipping on.
Looks like upon approval I’ll be sipping champagne and bourbon!
Smoke and Mirrors.
Thanks, Doc Logic. Won't be long before we reach the first potential meeting where we might get approval. Though possibly we could hear anytime. Interesting how automation seems to be aligning with approval!
beartrap12,
Great work! Looked at from lots of angles and gives great rational for each look. Best wishes.
dstock07734,
Look at the Nivo numbers again. Subcutaneous Nivo had more deaths confirmed related to drug toxicity (3) vs IV (1) with only one patient difference in enrollment. We now know that two different SC versions have come out with toxicity numbers that slightly favor IV vs SC delivery. This SC adverse events trend is not favorable to patients or safety first when considering safety of IV vs SC. Best wishes.
No, the CHM meeting isn't full UK approval, it may, or may not be required, but it isn't the approval we're waiting for. I've not backed off at all, if I'm right about the 150 days starting on submission we could hear tomorrow, or very shortly thereafter. If it's 150 from preliminary validation we're a little over a month away. Nothing says the UK must take the entire 150 day period, so regardless, approval could come any day.
If it's true that no CHM meeting was required, to me that would indicate they've made up their minds and it's only a matter of doing all that's expected of them before announcing the result.
If they were notified of approval before the open tomorrow, the question might be, do they announce it immediately, or better plan how they're doing it a day, or two later. Sadly it doesn't seem to matter when they decide to announce, it will be well before the opening bell and I'll be asleep if they should schedule a webcast before the bell, typically at 5:30 my time, 8:30 in New York. Many investors on the East Coast may not be looking for such a notification. I'd love to see a company announce on Saturday or Sunday that they'll be holding a webcast before the open on Monday, that would be enough to have me set an alarm and listen to what's happening.
Regardless if it's tomorrow, or in roughly the next month, we are in for some very interesting, and hopefully very profitable, times.
Gary
A 1.5 ounce serving of bourbon contains zero grams of sugar. Straight bourbon doesn't contain added sugar during the production process. The primary ingredients of bourbon are water, corn, rye or wheat, and malted barley, which undergo fermentation, distillation, and aging. During fermentation, yeast breaks down the sugars from the mash, creating carbon dioxide and alcohol.
No evidence of anything.
Right, they won't be visiting those sites but they'll be looking at the batch records and possibly records generated at those sites to confirm the L provided in the trial is the same they'll be making commercially at Sawston/state in the MAA.
?? Running off to another country ??
UK is quite well respected .. you’re just pissed they are working with NWBO ..
Not fighting against it …
Diff is uk is working with NWBO
NOT AGAINST US
In spite of all the delays
u sure seem to be worried about an approval
U have been here for over 10 years .. free of charge 🤣🤣🤣🤣as u say …
U would not be here FREE OF CHARGE ..
BASHERS get paid by someone ..and you are getting paid !!!
It's research for researches sake without having to burden true investors with BP decisions.
>>BP does pay a large amount to the FDA in fees. But they pay even more, proportionately, to the MHRA,
Unless bourbon is low sugar and low alcohol, I shouldn’t consume any.
I may be able to wet my beak, so to speak, however I might not have the will power to stop there
We know big pharma pays the bills for our fda and majority of docs on the panel will be bought and paid for !!!
Hence approvals elsewhere first should make the pathway more
Legit and not as corruptible …
But we know as longs nothing is a sure thing with our fda
nothing"? well that's not true, you know it.
you know all the achievements with the trail, manufacturing, patents and so on!
it all took longer than predicted but it happend!
so does approval and you are right on that point - it should have happend between 2016 and now as many (myself) believed it would and talking about in our comments- and we were wrong. blain and simple WRONG
but there always comes a time when we leave things behind, achieved goals, and an event , a release which seemingly never wiill come true CAME TRUE
(the same as i always say to friends and whoever. there comes a time after putin, after things worse, seemingly endless - seemingly no solution, enduring for so long. so we are used to it day by day, week by week. . . . . . to a point where these things are (seemingly) quite "normal" . . . . belong to the day, to the present.
but there comes a time . . . . . )
may have already occurred " in" the April CHM meeting . What else other than approval would you be referring to may have occurred "in " the meeting??You are attempting to back pedal. Surprised as that is not your style.
Hey LC, I'm sure everybody here is looking forward to a good and promising rat study from you. Got any more good ones?
What you seem to be missing is they are debating the timing of the MAA approval not the likelihood, which is considered to be very likely.
Doc, I personally don’t think the MHRA will inspect Charles River Labs' (formerly Cognate’s) or Fraunhofer’s manufacturing facilities, since they are not currently being used (or immediately planned) for initial DCVax commercial production.
I think, but I’m not sure if the MHRA is like the FDA, in that they will generally schedule a pre-license or pre-approval inspection of the intended commercial manufacturing facility after the midpoint in the review process, and request to view all phases of the production operations for the selected product under review in the marketing application.
Shutting down operations of a GMP facility for construction, maintenance, cleaning, and disinfection is complex, but routine, and would not effect anything unless a significant change to the plant and equipment occurs, which would usually require requalification. (except that a pre-approval inspection obviously could not be scheduled during the shutdown)
ski, are you asking if I think the UK inspectors need to look at the manufacturing sites used for the clinical trial, since only Sawston is indicated for commercial manufacturing at this time?
If so, my answer is no, it shouldn’t be necessary as long as there were no potential red flags raised during the review of the clinical trial patient records or manufacturing records from those sites that were sampled. However, that may not be the case, and not all inspectors/regulators are equally thorough, or think the same. Generally, the first marketing application and regulatory review for a new drug, or molecular entity, is more thorough and takes longer than subsequent marketing applications for additional use of an already approved drug. (since the appropriate nonclinical and manufacturing data may have already been reviewed by the Agency in the initial application)
Visits to potentially obsolete manufacturing sites is certainly one area of the 150-day accelerated review process that could, and probably will be cut to expedite the review from the standard timeline. As additional commercial manufacturing sites are added, they may be inspected at that time.
Right ATLnsider, as you indicate, in the UCLA combination studies with DCVax-L, the poly-ICLC is administered separately as an adjuvant. However, in the early studies with DCVax-Direct, it was used in the manufacturing process, which increased the potency. (poly I:C, or its derivative, poly-ICLC is included in the Direct patents, and the more recent hyperactive patents)
I'm talking about a PR for approval, not the occurrence of the CHM meeting. I've not seen any company announce that the meeting occurred.
Gary
Sometimes an end run is better than running up the middle.
Approval from the US FDA is a goal. It’s just not the first one.
There is a process to getting approvals in our FDA is very corrupt as you know since you work for the enemy that’s why we are going to get it approved in Europe the UK Canada then our FDA won’t be able to deny it when it’s already available elsewhere they would look like the incompetent fools that they areif they did attempt to deny it
Your boss is probably already shitting his trousers.
Update – May 2024
— rj (@sharpie510) May 19, 2024
“Stable appearance”.
Joel’s April brain scan continues to show stable post treatment appearance. It is such a relief and extraordinary news.
🫶
The DCVax® Platform For All Solid Tumor Cancers
💪$nwbo #glioblastoma #CancerVaccine
https://t.co/GQxd4PuHRU
The interim analysis data certainly does.
It’s equally ineffective though.
You know how many longs have said that and have left the board because this trial still hasn’t submitted a BLA to the FDA?
Guaranteed approval in 2016-2024 and still nothing.
The bashers move their goalpost more than anyone we’ve ever seen. That’s why we know they’re not here for the right reasons and they should all be just ignored. I would invite LC to the shareholder meeting. I’ll even pay his way there and back if he brings me his receipt, he can even sit right next to me and ask questions to his heart, but him and all his friends are cowards
Followers
|
1623
|
Posters
|
|
Posts (Today)
|
8
|
Posts (Total)
|
692656
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators XenaLives sentiment_stocks CaptainObvious Poor Man - Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |